Showing 781-790 of 2386 results for "".
- In Memoriam: June Halper, MSN, APN-C, FAAN, MSCNhttps://practicalneurology.com/news/in-memoriam-june-halper-msn-apn-c-faan-mscn/2470537/June Halper, MSN, ASPN-C, FAAN, MSCN passed away on July 24, 2024, at age 86. Ms. Halper was a founding member of the Consortium of Multiple Sclerosis Centers (CMSC) and served as the organization’s President from 1995 to 1997 and as its Executive Director/CEO from 1992 until her death. Ms.
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- FDA Rejects Application for Gene Therapy for Hunter Syndromehttps://practicalneurology.com/news/fda-rejects-application-for-gene-therapy-for-hunter-syndrome/2485648/The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec; REGENXBIO, Rockville, MD), meaning that, at this time, the FDA will not approve the investigational gene therapy for mucopolysaccha